Table 1.

Characteristics of the 237 HIV-infected children initiating LPV/r-based antiretroviral therapy and included in the analysis

Variable	Value	Missing data, %
Age on starting ART, months	10 (9–25.50)	0
Pretreatment viral load		13
<100,000 copies/ml	20 (8)	–
100,000–750,000 copies/ml	61 (26)	–
>750,000 copies/ml	125 (53)	–
Pretreatment body weight, kg	6.81 (5.32–7.90)	–
LPV/r dose, mg/m2	230/57.5	–
Pretreatment WAZ	−2.17 (−3.35–−1.21)	11
Pretreatment HAZ	−3.34 (−4.57–−3.41)	12
Pretreatment CD4%	18.80 (12.70–25.35)	5
Sex		0
Male	109 (46)	–
Female	128 (54)	–
WHO stage		18
Early	42 (22)	–
Moderate	147 (78)	–

Data are median (IQR) or n (%). ART, antiretroviral therapy; CD4%, CD4⁺ T-cell percentage; HAZ, height-for-age z-score; LPV/r, ritonavir-boosted lopinavir; WAZ, weight-for-age z-score.